Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes.

Reilly B, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R.

Blood Adv. 2019 Oct 8;3(19):2845-2858. doi: 10.1182/bloodadvances.2019000192.

2.

Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT2A amplification as a homogenously staining region.

Wang HY, Tanaka TN, Dell'Aquila M.

Br J Haematol. 2019 Aug;186(4):509. doi: 10.1111/bjh.15985. Epub 2019 May 28. No abstract available.

PMID:
31134617
3.

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A.

Blood Adv. 2019 Apr 23;3(8):1197-1210. doi: 10.1182/bloodadvances.2018030387. Review.

4.

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A.

J Clin Oncol. 2019 May 20;37(15):1336-1351. doi: 10.1200/JCO.18.02142. Epub 2019 Apr 10.

5.

MDS overlap disorders and diagnostic boundaries.

Tanaka TN, Bejar R.

Blood. 2019 Mar 7;133(10):1086-1095. doi: 10.1182/blood-2018-10-844670. Epub 2019 Jan 22. Review.

PMID:
30670443
6.

A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.

Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):346-352.e5. doi: 10.1016/j.clml.2018.02.017. Epub 2018 Mar 2.

PMID:
29572158
7.

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.

Sallman DA, Tanaka TN, List A, Bejar R.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):613-620. doi: 10.1016/j.clml.2017.09.018. Epub 2017 Sep 25. Review.

PMID:
29025689
8.

Characterization of cross-reactive norovirus-specific monoclonal antibodies.

Kou B, Crawford SE, Ajami NJ, Czakó R, Neill FH, Tanaka TN, Kitamoto N, Palzkill TG, Estes MK, Atmar RL.

Clin Vaccine Immunol. 2015 Feb;22(2):160-7. doi: 10.1128/CVI.00519-14. Epub 2014 Nov 26.

9.

Identification of an epitope common to genogroup 1 "norwalk-like viruses".

Hale AD, Tanaka TN, Kitamoto N, Ciarlet M, Jiang X, Takeda N, Brown DW, Estes MK.

J Clin Microbiol. 2000 Apr;38(4):1656-60.

10.

Attachment and entry of recombinant Norwalk virus capsids to cultured human and animal cell lines.

White LJ, Ball JM, Hardy ME, Tanaka TN, Kitamoto N, Estes MK.

J Virol. 1996 Oct;70(10):6589-97.

11.

Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies.

Hardy ME, Tanaka TN, Kitamoto N, White LJ, Ball JM, Jiang X, Estes MK.

Virology. 1996 Mar 1;217(1):252-61.

12.

Rotavirus gene detection with biotinylated single-stranded RNA probes.

Bellinzoni R, Xi JA, Tanaka TN, Scodeller E, Estes MK.

Mol Cell Probes. 1989 Sep;3(3):233-44.

PMID:
2552300
13.

Molecular characterization of three rabbit rotavirus strains.

Tanaka TN, Conner ME, Graham DY, Estes MK.

Arch Virol. 1988;98(3-4):253-65.

PMID:
2831858

Supplemental Content

Loading ...
Support Center